INTRODUCTION
Ovarian cancer is a chemotherapy-sensitive disease that is treated at the first-line using platinum-and taxane-based chemotherapy. The disease recurs after first-line treatment in the majority of patients (80%), who must be retreated at subsequent recurrences as long as the tumour is responsive to chemotherapy. 1 Response rates to chemotherapy decline with each subsequent recurrence due to the onset of drug resistance. 1 Identifying appropriate utility values to inform cost-effectiveness analysis is a common problem. The aim of this study was to review health state utility values (HSUVs) for patients with advanced ovarian cancer and make recommendations about their use in the economic evaluation of a targeted maintenance therapy for platinum-sensitive recurrent ovarian cancer (PSROC).
RESULTS
A total of 1200 publications were identified through literature searches, and of these, 10 publications, representing five primary sources of utility values, were found. Two were derived from trial-based patientreported EQ-5D profiles; one derived profiles from patients with ovarian cancer and utility values from a sample of the general population using a SG; one derived HSUVs from patients with a prior diagnosis of ovarian cancer and healthy volunteers using TTO and VAS; one non ovarian cancer-specific study derived utilities using TTO.
Included studies reported utilities for 18 different health states. Further, 2 additional health states were identified in a mixed patient population study, where the majority of patients (70%) had advanced ovarian cancer. Utilities derived using direct elicitation methods are presented in Table 1 . Utilities derived using indirect elicitation methods are presented in Table 2 . The trial-based estimates of health state utility shown above were derived by pooling patients across all comparators in two clinical trials (OVA-301 and ICON7). These estimates have been used in all of the recent ovarian cancer technology assessments submitted to NICE (TA 222, TA 284, and TA 285). Overall, there is insufficient evidence to conclude whether or not health state utilities differ across these treatments. Furthermore, none of the trial-based estimates made any allowances for the reduction in utility associated with treatmentrelated adverse events, on the basis that since EQ-5D values were obtained from patients at a number of different time points during treatment, the effects of adverse events would already be accounted for. Since utility estimates were pooled across treatment groups, this assumption implies that the profile of adverse events is the same for all treatments.
None of the studies included in this review reported values for patients receiving maintenance therapy. Where comparisons were possible, utility values differed widely: remission 0.72-0.977; progression-free after recurrence 0.4-0.718; progressive disease 0.27-0.725. However, there is some evidence to suggest that utility value associated with the progression-free health state increases with the length of progressionfree survival.
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CONCLUSIONS
• There is limited health-state utility data for advanced ovarian cancer and wide variations in sample size, methods of elicitation, populations used to provide utility values, and health state descriptions.
• Given the limitations of the current evidence base, additional methods, such as mapping algorithms, should be considered.
• Further research is needed to provide robust estimates to populate an economic model for a targeted maintenance therapy for PSROC.
